Phaseline

Companies › Ascentawits Pharmaceuticals

Ascentawits Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AST-001–Phase 1Solid TumorAug 2027
AST-3424–Phase 1Advanced Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06239155AST-3424Phase 1Advanced Solid TumorsOncologyNov 2025
NCT06245330AST-001Phase 1Solid TumorOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.